These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 32938226)
1. Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer. Liang F; Zhang H; Gao H; Cheng D; Zhang N; Du J; Yue J; Du P; Zhao B; Yin L Exp Biol Med (Maywood); 2021 Feb; 246(4):459-466. PubMed ID: 32938226 [TBL] [Abstract][Full Text] [Related]
2. Epigenetic Regulation of CDH1 Is Altered after HOXB7-Silencing in MDA-MB-468 Triple-Negative Breast Cancer Cells. Paço A; Leitão-Castro J; Freitas R Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680970 [TBL] [Abstract][Full Text] [Related]
3. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines. Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216 [TBL] [Abstract][Full Text] [Related]
4. Methyl CpG binding protein MBD2 has a regulatory role on the BRCA1 gene expression and its modulation by resveratrol in ER+, PR+ & triple-negative breast cancer cells. Sahu RK; Tandon S; Singh S; Das BC; Hedau ST BMC Cancer; 2024 May; 24(1):566. PubMed ID: 38711004 [TBL] [Abstract][Full Text] [Related]
5. Resveratrol enhances the sensitivity of FL118 in triple-negative breast cancer cell lines via suppressing epithelial to mesenchymal transition. Yar Saglam AS; Kayhan H; Alp E; Onen HI Mol Biol Rep; 2021 Jan; 48(1):475-489. PubMed ID: 33389483 [TBL] [Abstract][Full Text] [Related]
6. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro. Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of endothelin receptor B inhibits the progression of triple-negative breast cancer. Gu X; Han S; Cui M; Xue J; Ai L; Sun L; Zhu X; Wang Y; Liu C Ann N Y Acad Sci; 2019 Jul; 1448(1):5-18. PubMed ID: 30900271 [TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer. Wang H; Wu D; Cai L; Li X; Zhang Z; Chen S J Cell Mol Med; 2020 Jun; 24(12):6869-6882. PubMed ID: 32394588 [TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2. Zhang G; Li H; Sun R; Li P; Yang Z; Liu Y; Wang Z; Yang Y; Yin C J Cell Mol Med; 2019 May; 23(5):3271-3279. PubMed ID: 30825262 [TBL] [Abstract][Full Text] [Related]
10. MYC and DNMT3A-mediated DNA methylation represses microRNA-200b in triple negative breast cancer. Pang Y; Liu J; Li X; Xiao G; Wang H; Yang G; Li Y; Tang SC; Qin S; Du N; Zhang H; Liu D; Sun X; Ren H J Cell Mol Med; 2018 Dec; 22(12):6262-6274. PubMed ID: 30324719 [TBL] [Abstract][Full Text] [Related]
11. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells. Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532 [TBL] [Abstract][Full Text] [Related]
12. S-Adenosylmethionine Inhibits Cell Growth and Migration of Triple Negative Breast Cancer Cells through Upregulating MiRNA-34c and MiRNA-449a. Coppola A; Ilisso CP; Stellavato A; Schiraldi C; Caraglia M; Mosca L; Cacciapuoti G; Porcelli M Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396625 [TBL] [Abstract][Full Text] [Related]
13. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331 [TBL] [Abstract][Full Text] [Related]
14. A high expression ratio of RhoA/RhoB is associated with the migratory and invasive properties of basal-like Breast Tumors. Privat M; Cavard A; Zekri Y; Ponelle-Chachuat F; Molnar I; Sonnier N; Bignon YJ Int J Med Sci; 2020; 17(17):2799-2808. PubMed ID: 33162807 [TBL] [Abstract][Full Text] [Related]
15. δEF1 associates with DNMT1 and maintains DNA methylation of the E-cadherin promoter in breast cancer cells. Fukagawa A; Ishii H; Miyazawa K; Saitoh M Cancer Med; 2015 Jan; 4(1):125-35. PubMed ID: 25315069 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer. Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437 [TBL] [Abstract][Full Text] [Related]
17. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587 [TBL] [Abstract][Full Text] [Related]
18. [Inhibition of Histone Deacetylases Reverses Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through a Slug Mediated Mechanism]. Rahimian A; Barati G; Mehrandish R; Mellati AA Mol Biol (Mosk); 2018; 52(3):474-481. PubMed ID: 29989579 [TBL] [Abstract][Full Text] [Related]
19. Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion. Si L; Fu J; Liu W; Hayashi T; Nie Y; Mizuno K; Hattori S; Fujisaki H; Onodera S; Ikejima T Mol Cell Biochem; 2020 Jan; 463(1-2):189-201. PubMed ID: 31612353 [TBL] [Abstract][Full Text] [Related]
20. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]